Indraprastha Medical Corporation Intrinsic Value
Indraprastha Medical Corporation (INDRAMEDCO) median intrinsic value is ₹198.26 from 10 valuation models (range ₹80–₹328), vs current price ₹362.90 — -45.4% downside (Trading Above Calculated Value), margin of safety -83.0%. See INDRAMEDCO P/B ratio to compare market price against book value per share.
INDRAMEDCO Valuation Methods Summary — DCF, Graham Number & P/E
Indraprastha Medical Corporation intrinsic value across 10 models vs current price ₹362.90 — upside/downside and value range per method. Check INDRAMEDCO company valuation to track the company's total market size over time.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹246.00 | ₹196.80 - ₹295.20 | -32.2% | EPS: ₹20.50, Sector P/E: 12x |
| Book Value Method | asset | ₹80.43 | ₹72.39 - ₹88.47 | -77.8% | Book Value/Share: ₹80.43, P/B: 1.0x |
| Revenue Multiple Method | revenue | ₹135.13 | ₹121.62 - ₹148.64 | -62.8% | Revenue/Share: ₹168.91, P/S: 0.8x |
| EBITDA Multiple Method | earnings | ₹198.26 | ₹178.43 - ₹218.09 | -45.4% | EBITDA: ₹304.00Cr, EV/EBITDA: 6x |
| Simple DCF (5Y) | dcf | ₹231.80 | ₹185.44 - ₹278.16 | -36.1% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹328.00 | ₹295.20 - ₹360.80 | -9.6% | EPS Growth: 20.0%, Fair P/E: 16.0x |
| Growth Adjusted P/E | growth | ₹171.22 | ₹154.10 - ₹188.34 | -52.8% | Revenue Growth: 8.8%, Adj P/E: 8.4x |
| ROE Based Valuation | profitability | ₹326.96 | ₹294.26 - ₹359.66 | -9.9% | ROE: 25.4%, P/E Multiple: 16x |
| Graham Defensive Method | conservative | ₹160.87 | ₹144.78 - ₹176.96 | -55.7% | EPS: ₹20.50, BVPS: ₹80.43 |
| Dividend Yield Method | dividend | ₹114.29 | ₹102.86 - ₹125.72 | -68.5% | DPS: ₹4.00, Target Yield: 3.5% |
INDRAMEDCO Intrinsic Value vs Market Price — All Valuation Models
Indraprastha Medical Corporation fair value range ₹80–₹328 vs current market price ₹362.90 across 10 valuation models. For current market price and key ratios, visit Indraprastha Medical Corporati share price today.
INDRAMEDCO Intrinsic Value Analysis — Undervalued or Overvalued?
Indraprastha Medical Corporation median intrinsic value ₹198.26, current price ₹362.90 — Trading Above Calculated Value by 45.4%, margin of safety -83.0%.
What is the intrinsic value of INDRAMEDCO?
Based on our comprehensive analysis using 10 different valuation methods, the estimated intrinsic value of Indraprastha Medical Corporation (INDRAMEDCO) is ₹198.26 (median value). With the current market price of ₹362.90, this represents a -45.4% variance from our estimated fair value.
The valuation range spans from ₹80.43 to ₹328.00, indicating ₹80.43 - ₹328.00.
Is INDRAMEDCO undervalued or overvalued?
Based on our multi-method analysis, Indraprastha Medical Corporation (INDRAMEDCO) appears to be trading above calculated value by approximately 45.4%.
INDRAMEDCO Financial Health — Key Ratios vs Industry Benchmarks
Indraprastha Medical Corporation financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 5.15 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 25.4% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 18.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 1.57x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
INDRAMEDCO Cash Flow Quality — Operating & Free Cash Flow
Indraprastha Medical Corporation operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹157 Cr | ₹102 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹200 Cr | ₹121 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹145 Cr | ₹91 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹94 Cr | ₹57 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹27 Cr | ₹18 Cr | Positive Free Cash Flow | 8/10 |